BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iwase H, Shimada M, Tsuzuki T, Hirashima N, Okeya M, Hibino Y, Ryuge N, Yokoi M, Kida Y, Kuno T, Tanaka Y, Kato B, Esaki M, Urata N, Kato E. Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial. Oncology 2013;84:342-9. [DOI: 10.1159/000348383] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Y, Li K, Diao D, Zhu K, Shi L, Zhang H, Yuan D, Guo Q, Wu X, Liu D, Dang C. Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro. Lab Invest 2013;93:1276-87. [DOI: 10.1038/labinvest.2013.124] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
2 Ji Y, Qiu G, Sheng L, Sun X, Zheng Y, Chen M, Du X. A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. J Thorac Dis 2016;8:451-8. [PMID: 27076940 DOI: 10.21037/jtd.2016.02.70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. J Cancer 2017;8:3242-50. [PMID: 29158796 DOI: 10.7150/jca.20835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Wang H, Li G, Chen L, Duan Y, Zou C, Hu C. Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients. J Thorac Dis 2017;9:646-54. [PMID: 28449472 DOI: 10.21037/jtd.2017.03.105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Ji Y, Du X, Tian Y, Sheng L, Cheng L, Chen Y, Qiu G, Zhou X, Bao W, Zhang D, Chen M. A phase II study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Oncotarget 2017;8:83022-9. [PMID: 29137320 DOI: 10.18632/oncotarget.20938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Takahashi T, Kaneoka Y, Maeda A, Takayama Y, Seita K. Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma. Updates Surg 2021. [PMID: 34559400 DOI: 10.1007/s13304-021-01167-4] [Reference Citation Analysis]
7 Abdelgawad IA, Radwan NH, Hassanein HR. KIAA0101 mRNA expression in the peripheral blood of hepatocellular carcinoma patients: Association with some clinicopathological features. Clin Biochem 2016;49:787-91. [PMID: 26968109 DOI: 10.1016/j.clinbiochem.2015.12.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
8 Fang M, Song T, Liang X, Lv S, Li J, Xu H, Luo L, Jia Y. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma. Oncotarget 2017;8:37080-90. [PMID: 28415745 DOI: 10.18632/oncotarget.16180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Song T, Liang X, Fang M, Wu S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther 2015;15:1157-69. [PMID: 26235427 DOI: 10.1586/14737140.2015.1074041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
10 Ojima T, Nakamura M, Nakamori M, Katsuda M, Hayata K, Maruoka S, Shimokawa T, Yamaue H. Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus. Oncology 2018;95:116-20. [DOI: 10.1159/000488861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Guo S, Liu F, Liu H, Wu Y, Zhang X, Ye W, Luo G, Li Q, Chen N, Hu N, Wang B, Zhang J, Lin M, Feng H, Qiu B. A Prospective Phase II Study of Simultaneous Modulated Accelerated Radiotherapy Concurrently With CDDP/S1 for Esophageal Squamous Cell Carcinoma in the Elderly. Front Oncol 2021;11:760631. [PMID: 34900709 DOI: 10.3389/fonc.2021.760631] [Reference Citation Analysis]
12 Wang X, Liu X, Li D, Wang X, Huang W, Li B. Concurrent Selective Lymph Node Radiotherapy and S-1 Plus Cisplatin for Esophageal Squamous Cell Carcinoma: A Phase II Study. Ann Surg Oncol 2019;26:1886-92. [PMID: 30805810 DOI: 10.1245/s10434-019-07264-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yoon DH, Jang G, Kim JH, Kim YH, Kim JY, Kim HR, Jung HY, Lee GH, Song HY, Cho KJ, Ryu JS, Kim SB. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2015;91:489-96. [PMID: 25680595 DOI: 10.1016/j.ijrobp.2014.11.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
14 Tomasello G, Ghidini M, Barni S, Passalacqua R, Petrelli F. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. Expert Rev Clin Pharmacol 2017;10:649-60. [PMID: 28349718 DOI: 10.1080/17512433.2017.1313112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Ojima T, Nakamura M, Nakamori M, Katsuda M, Hayata K, Kitadani J, Maruoka S, Shimokawa T, Yamaue H. Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. Oncotarget 2019;10:847-55. [PMID: 30783514 DOI: 10.18632/oncotarget.26614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 So B, Marcu LG, Olver I, Gowda R, Bezak E. Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas. Acta Oncologica 2017;56:899-908. [DOI: 10.1080/0284186x.2017.1307518] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ, Chung HS, Lee H, Shin SK, Lee SK, Lee CG, Lee YC. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Digestive and Liver Disease 2014;46:846-53. [DOI: 10.1016/j.dld.2014.05.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
18 Liu F, Wang C, Hu T, Wang W. S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2018;97:e0397. [PMID: 29642202 DOI: 10.1097/MD.0000000000010397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Liu WY, Wu XU, Liao CQ, Shen J, Li J. Apoptotic effect of gambogic acid in esophageal squamous cell carcinoma cells via suppression of the NF-κB pathway. Oncol Lett 2016;11:3681-5. [PMID: 27284372 DOI: 10.3892/ol.2016.4437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
20 Lv S, Fang M, Yang J, Zhan W, Jia Y, Xu H, Song T. Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer. Onco Targets Ther 2016;9:5389-97. [PMID: 27660461 DOI: 10.2147/OTT.S107668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Jiao Y, Shen Y, Yan H, Liu Y, Tan H, Li J. Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer. Pak J Med Sci 2016;32:1141-5. [PMID: 27882010 DOI: 10.12669/pjms.325.10632] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Li M, Fu C, Zhang W, Huang W, Wang Z, Zhou T, Lin H, Li B. Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol 2016;89:20150476. [PMID: 26891913 DOI: 10.1259/bjr.20150476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
23 Wen Y, Zhao Z, Miao J, Yang Q, Gui Y, Sun M, Tian H, Jia Q, Liao D, Yang C, Du X. S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial. Medicine (Baltimore) 2017;96:e8998. [PMID: 29245275 DOI: 10.1097/MD.0000000000008998] [Reference Citation Analysis]
24 Wang W, Xing D, Song Y, Liu F. Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. Medicine (Baltimore) 2018;97:e0164. [PMID: 29561425 DOI: 10.1097/MD.0000000000010164] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]